GlassScriptPhysician profile
David R Hakas
NPI 1578581930
$1,223.26
in general payments reported to CMS, 2019-2025
14 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $109 · 2024: $297 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $262.72 | 2019 | |
| Fresenius USA Marketing, INC. | $151.42 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $146.08 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $122.35 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $108.79 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $101.76 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $72.33 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.87 | 2024-2025 | |
| Ardelyx, INC. | $52.22 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $44.37 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $40.48 | 2020 | |
| Alkermes, INC. | $25.66 | 2025 | Vivitrol |
| Ani Pharmaceuticals, INC. | $18.23 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hakas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.